Anti-relapse therapy in children with chronic secondary pyelonephritis: evaluation of effectiveness and rationale for a differentiated approach

Currently, there is no unified system of anti-relapse treatment of pyelonephritis in children.

Purpose. To assess the feasibility of prescribing and effectiveness of various anti-relapse therapy regimens to prevent exacerbations of the disease in children with chronic secondary pyelonephritis.

Materials and Methods. The study involved 158 children with chronic secondary pyelonephritis aged 2 to 14 years, including 130 (82.3%) girls and 28 boys (17.7%). The children were divided into the following groups: Group A (n=32) — furazidine — 14 days, anti-relapse therapy after 12 months; Group B (n=34) — furazidine — 14 days, then — Canephron 1 month, anti–relapse therapy after 12 months; Group C (n=34) — Canephron 3 months, anti-relapse therapy after 12 months; Group D (n=30) — furazidine — 14 days, then — Canephron 1 month of anti–relapse therapy after 6 months; Group E (n=28) — furazidine — 14 days of anti-relapse therapy was not performed. Results. It was found that the recurrence rate of chronic secondary pyelonephritis for a 24-month follow-up in Group A was 28.1% (n=9), in Group B, 14.7% (n=5), in Group C, 20.5% (n=7), in Group D, 10% (n=3), in Group E, 42.9% (n=12). The timing of relapse of chronic secondary pyelonephritis was different, with the largest increase in the proportion of patients with exacerbations in the period from 6 to 12 months. The average recurrence rate per year in the catamnesis in all children (n=158) was 1.4 [1.2–1.6], during the prospective follow-up, a statistically significant (p=0.001) decrease in the recurrence rate to 0.36 [0.2–0.79] was noted. Conclusion. The data obtained confirm the feasibility of anti-relapse therapy in children with chronic secondary pyelonephritis.

1. Chang S.L., Shortliffe L.D. Pediatric urinary tract infections. Pediatr Clin North Am 2006; 53(3): 379–400. DOI: 10.1016/j.pcl.2006.02.011

2. Balighian E., Burke M. Urinary Tract Infections in Children. Pediatr Rev 2018; 39(1): 3–12. DOI: 10.1542/pir.2017–0007

3. Hewitt I.K., Pennesi M., Morello W., Ronfani L., Montini G. Antibiotic Prophylaxis for Urinary Tract Infection-Related Renal Scarring: A Systematic Review. Pediatrics 2017; 139(5): e20163145. DOI: 10.1542/peds.2016–3145

4. Lee J.N., Byeon K.H., Woo M.J., Baek H.S., Cho M.H., Jeong S.Y. et al. Susceptibility of the Index Urinary Tract Infection to Prophylactic Antibiotics Is a Predictive Factor of Breakthrough Urinary Tract Infection in Children with Primary Vesicoureteral Reflux Receiving Continuous Antibiotic Prophylaxis. J Korean Med Sci 2019; 34(21): e156. DOI: 10.3346/jkms.2019.34.e156

5. Williams G., Craig J.C. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2019; 4(4): CD001534. DOI: 10.1002/14651858.CD001534.pub4

6. Pigrau C., Escolà-Vergé L. Recurrent urinary tract infections: from pathogenesis to prevention. Med Clin (Barc) 2020; 155(4): 171–177. English, Spanish. DOI: 10.1016/j.medcli.2020.04.026

7. Brandström P., Hansson S. Long-term, low-dose prophylaxis against urinary tract infections in young children. Pediatr Nephrol 2015; 30(3): 425–432. DOI: 10.1007/s00467–014–2854-z

8. Alsubaie S.S., Barry M.A. Current status of long-term antibiotic prophylaxis for urinary tract infections in children: An antibiotic stewardship challenge. Kidney Res Clin Pract 2019; 38(4): 441–454. DOI: 10.23876/j.krcp.19.091

9. Sorlózano-Puerto A., Gómez-Luque J.M., Luna-Del-Castillo J.D., Navarro-Marí J.M., Gutiérrez-Fernández J. Etiological and Resistance Profile of Bacteria Involved in Urinary Tract Infections in Young Children. Biomed Res Int 2017; 2017: 4909452. DOI: 10.1155/2017/4909452

10. Nagler E.V., Williams G., Hodson E.M., Craig J.C. Interventions for primary vesicoureteric reflux. Cochrane Database Syst Rev 2011; 6: CD001532. DOI: 10.1002/14651858. CD001532.pub4 11. Strohmeier Y., Hodson E.M., Willis N.S., Webster A.C., Craig J.C. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2014; 7: CD003772. DOI: 10.1002/14651858.CD003772.pub4

11. Ovcharenko L.S., Vertegel A.A., Andrienko T.G. Therapy of repeated episodes of urinary tract infection in children with an assessment of the sensitivity profile of uropathogens. Sovremennaya pediatriya 2017; 2(82): 111–116. (in Russ.) DOI: 10.15574/SP.2017.82.111

12. Practical guide to anti-infective chemotherapy. Editors L.S. Strachunsky, Yu.B. Belousov, S.N. Kozlov Smolensk: NIIAH SGMA, 2007; 462 p. (in Russ.)

13. Afshar K., Stothers L., Scott H., MacNeily A.E. Cranberry juice for the prevention of pediatric urinary tract infection: a randomized controlled trial. J Urol 2012; 188(4 Suppl): 1584– 1587. DOI: 10.1016/j.juro.2012.02.031

14. Salo J., Uhari M., Helminen M., Korppi M., Nieminen T., Pokka T., Kontiokari T. Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized placebo-controlled trial. Clin Infect Dis 2012; 54(3): 340– 346. DOI: 10.1093/cid/cir801

15. Jepson R.G., Williams G., Craig J.C. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2012; 10(10): CD001321. DOI: 10.1002/14651858.CD001321.pub5

16. Meena J., Thomas C.C., Kumar J., Raut S., Hari P. Non-antibiotic interventions for prevention of urinary tract infections in children: a systematic review and meta-analysis of randomized controlled trials. Eur J Pediatr 2021; 180(12): 3535– 3545. DOI: 10.1007/s00431–021–04091–2

17. Wagenlehner F.M., Abramov-Sommariva D., Höller M., Steindl H., Naber K.G. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int 2018; 101(3): 327–336. DOI: 10.1159/000493368

18. Brenneis C., Künstle G., Haunschild J. Spasmolytic Activity of Canephron® N on the Contractility of Rate and Human Isolated Urinary Bladder. 13th International Congress of the Society for Ethnopharmacology. Graz, Austria. 2012; 2–6

19. Künstle G., Brenneis C., Haunschild J. Efficacy of Canephron® N against bacterial adhesion, inflammation and bladder hyperactivity. Eur Urol Suppl 2013; 12:e671. DOI: 10.1016/S1569–9056(13)61153–7

20. Naber K.G. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol 2013; 5: 39–46. DOI: 10.2147/RRU.S39288

21. Höller M., Steindl H., Abramov-Sommariva D., Wagenlehner F., Naber K.G., Kostev K. Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis. Antibiotics (Basel) 2021; 10(6): 685. DOI: 10.3390/antibiotics10060685

22. Eremeeva A.V., Dlin V.V., Kudlay D.A., Korsunskiy A.A., Galeeva E.V., Shestakova I.V. Non-invasive fibrogenesis markers in children with acute and chronic secondary pyelonephritis. Pediatria n.a. G.N. Speransky. 2021; 100(3): 88–96. (in Russ.) DOI: 10.24110/0031–403X-2021–100–3–88–96

23. Tsai W.C., Wu H.Y., Peng Y.S., Ko M.J., Wu M.S., Hung K.Y. et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore) 2016; 95(11): e3013. DOI: 10.1097/MD.0000000000003013